Who are Istodax's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low dose valproate, Duvyzat, Farydak, Beleodaq, BELINOSTAT, Zolinza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/romidepsin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Istodax — Competitive Intelligence Brief

Istodax (ROMIDEPSIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone Deacetylase Inhibitor. Area: Oncology.

marketed Histone Deacetylase Inhibitor HDACs Oncology Recombinant protein Live · refreshed every 30 min

Target snapshot

Istodax (ROMIDEPSIN) — Teva Pharms Usa Inc. Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Istodax TARGET	ROMIDEPSIN	Teva Pharms Usa Inc	marketed	Histone Deacetylase Inhibitor	HDACs	2009-01-01
Low dose valproate	Low dose valproate	Mario Negri Institute for Pharmacological Research	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDACs)
Duvyzat	GIVINOSTAT	Italfarmaco Spa	marketed	Histone Deacetylase Inhibitor [EPC]		2024-01-01
Farydak	PANOBINOSTAT	Secura	marketed	Histone Deacetylase Inhibitor	Histone deacetylase 4	2015-01-01
Beleodaq	belinostat	Acrotech Biopharma	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 1	2014-01-01
BELINOSTAT	BELINOSTAT		marketed	Histone Deacetylase Inhibitor [EPC]		2014-01-01
Zolinza	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone Deacetylase Inhibitor class)

Secura · 1 drug in this class
Teva Pharms Usa Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Istodax — Competitive Intelligence Brief. https://druglandscape.com/ci/romidepsin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab